Aldeyra Claims Success In Final Phase III For First-In-Class Dry Eye Drug
Both Co-Primary Endpoints Hit In TRANQUILITY-2
Executive Summary
The company plans to submit an NDA for reproxalap for dry eye disease based on the results and hailed the crossover trial design as unique in the therapeutic area.